Validating Mark2 Gene Polymorphism As a Predictor of Response to Lithium Treatment in Bipolar Patients Publisher Pubmed



Afjeh SSA¹ ; Shams J² ; Hamednia S³ ; Boshehri B⁴ ; Amini A⁵ ; Omrani A⁶ ; Omrani MD^{1, 7} Show Affiliations
Source: Iranian Biomedical Journal Published:2022

Abstract

Background: Lithium is a therapeutic option for the treatment of the acute phase of the bipolar disorder and long-term management of this disorder. However, it is estimated that 10 to 60% of patients do not properly response to this medication. Methods: To investigate the role of MARK2 gene in response to lithium, we genotyped the MARK2 rs10792421 polymorphism in Iranian bipolar patients using ARMS-PCR. Results: Results of this study showed a significant association of this polymorphism with response to lithium. The A allele was more frequent in the responder than the non-responder group and also in the semi-responder group compared to the non-responder group in the codominant model of analysis. AA and AG genotypes were more frequent in both the responder and semi-responder groups compared to the non-responder group in dominant model of analysis. Conclusion: Based on the findings of the current study, the rs10792421 variant of MARK2 gene could be considered as a potential biomarker for predicting the treatment outcome of bipolar disorder type 1 in Iranian population. © 2022, Pasteur Institute of Iran. All rights reserved.